Implantable Cardioverter Defibrillator (ICD) Patients and Inhalation Aromatherapy
Launched by TC ERCIYES UNIVERSITY · Mar 7, 2025
Trial Information
Current as of April 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals who were willing to participate in the study,
- • aged between 18 and 65 years,
- • with no physical or mental health issues that would hinder communication,
- • had an ICD implanted at least 6 months ago,
- • had a battery life of at least 3 months,
- • had a fatigue level of 3 or higher on the Visual Analog Scale for Fatigue (VAS-F),
- • had an EF of 40% or higher,
- • and were visiting the cardiology outpatient clinic for ICD control
- Exclusion Criteria:
- • Individuals receiving anxiolytic or antidepressant treatment,
- • those with respiratory system diseases (such as asthma, bronchitis, or chronic obstructive pulmonary disease), 19,231 characters left
- • those with a known sensitivity to the essential oils used, and individuals with an olfactory impairment
About Tc Erciyes University
TC Erciyes University is a leading academic institution in Turkey, dedicated to advancing medical research and healthcare through innovative clinical trials. With a strong emphasis on scientific excellence and collaboration, the university leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies aimed at improving patient outcomes. Committed to ethical standards and regulatory compliance, TC Erciyes University fosters a research environment that promotes the development of new therapies and interventions, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Adana, Yüreğir, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
